Perjeta Solution For Injection 30Mg Drug Medication Dosage Information
show timeout overlay link

Your Session Is About to Expire

This online session is about to expire due to inactivity. Click Continue to return to page.

  • Weekly Ad

PERJETA: Solution for injection (30mg)

Also see:
  • Get answers to Frequently Asked Questions (FAQs)
  • Find other class related drugs
  • Find additional patient usage statistics

Visit Drug Summary Page
Drug Image file default-drug-image.png


What is this Medicine?

PERTUZUMAB (per TOOZ ue mab) is a monoclonal antibody. It is used to treat breast cancer.

In-Depth Information

PERJETA 420mg/14mL Solution for Injection

NDC: 502420145
  • Prescription Required
  • Not a Controlled Drug
    (CSA Schedule)
  • FDA Approved




FDA approved for the following conditions:
Breast Cancer

Storage Information
Refrigerate (between 36 and 46 degrees F)
Protect from light
Discard product if it contains particulate matter, is cloudy, or discolored
Diluted product if not used immediately can be stored at 36 to 46 degrees F for up to 24 hours
Do not freeze
Store in outer carton when not in use
PERJETA 420mg/14mL Solution for Injection

Reported Side Effects for PERJETA 420mg/14mL Solution for Injection

Infusion-related Reactions Incidence:
<1.0%*
Severity: SEVERE
Onset: RAPID
Vomiting Incidence:
<5.3%*
Severity: SEVERE
Onset: EARLY
Fluid Retention Incidence:
<0.5%*
Severity: SEVERE
Onset: DELAYED
Weakness Incidence:
<2.5%*
Severity: SEVERE
Onset: DELAYED
Low Platelet Count Incidence:
<11.8%*
Severity: SEVERE
Onset: DELAYED
Lightheadedness Incidence:
<1.3%*
Severity: SEVERE
Onset: EARLY
Muscle Pain Incidence:
<1.0%*
Severity: SEVERE
Onset: EARLY
Elevated Hepatic Enzymes Incidence:
<3.9%*
Severity: SEVERE
Onset: DELAYED
Headache Incidence:
<1.2%*
Severity: SEVERE
Onset: EARLY
Fever Incidence:
<1.2%*
Severity: SEVERE
Onset: EARLY
Nose Bleed Incidence:
<1.3%*
Severity: SEVERE
Onset: DELAYED
Shortness Of Breath Incidence:
<1.0%*
Severity: SEVERE
Onset: EARLY
Upset Stomach Incidence:
<2.7%*
Severity: SEVERE
Onset: EARLY
Upset Stomach Incidence:
<1.4%*
Severity: SEVERE
Onset: EARLY
Loose Stools Incidence:
<11.8%*
Severity: SEVERE
Onset: EARLY
Decreased Appetite Incidence:
<1.9%*
Severity: SEVERE
Onset: DELAYED
Skin Rash Incidence:
<1.3%*
Severity: SEVERE
Onset: EARLY
Joint Pain Incidence:
<0.8%*
Severity: SEVERE
Onset: DELAYED
Infection Incidence:
0.7%*
Severity: SEVERE
Onset: DELAYED
Tired Incidence:
0.9-3.9%*
Severity: SEVERE
Onset: EARLY
Low White Blood Cells Incidence:
0.9-57.4%*
Severity: SEVERE
Onset: DELAYED
Nerve Pain Incidence:
0.9-1.2%*
Severity: SEVERE
Onset: DELAYED
Secretion Of Tears Incidence:
0.9-14.0%*
Severity: MILD
Onset: EARLY
Chills Incidence:
>1.0%*
Severity: MILD
Onset: RAPID
Heart Failure Incidence:
1.0-4.0%*
Severity: SEVERE
Onset: DELAYED
Anaphylactoid Reactions Incidence:
1.3-10.1%*
Severity: SEVERE
Onset: RAPID
Fluid Around The Lungs Incidence:
1.4-5.2%*
Severity: SEVERE
Onset: DELAYED
Anemia Incidence:
1.4-17.1%*
Severity: SEVERE
Onset: DELAYED
Antibody Formation Incidence:
2.8%*
Severity: MODERATE
Onset: DELAYED
Itching Incidence:
2.8-14.0%*
Severity: MILD
Onset: RAPID
Hair Loss Incidence:
2.8-60.9%*
Severity: MILD
Onset: DELAYED
Inability To Sleep Incidence:
3.7-21.1%*
Severity: MILD
Onset: EARLY
Mouth Ulcers Incidence:
4.6-16.3%*
Severity: MODERATE
Onset: DELAYED
Metallic Taste Incidence:
4.6-21.1%*
Severity: MILD
Onset: EARLY
Low White Blood Cell Counts Incidence:
4.7-19.4%*
Severity: SEVERE
Onset: DELAYED
Cough Incidence:
5.3-11.8%*
Severity: MILD
Onset: DELAYED
Dry Skin Incidence:
5.6-10.6%*
Severity: MILD
Onset: DELAYED
Hand And Foot Syndrome Incidence:
6.9-10.7%*
Severity: MODERATE
Onset: DELAYED
Constipation Incidence:
15.8-22.7%*
Severity: MODERATE
Onset: DELAYED
*This is an approximate aggregated range of reported side effects from clinical studies performed on this drug. Your experience with this drug may be different.
Pregnancy & Lactation Information
FIRST Trimester

Class D - Adequate well-controlled or observational studies in pregnant women have demonstrated a risk to the fetus. However, the benefits of therapy may outweigh the potential risk. For example, the drug may be acceptable if needed in a life-threatening situation or serious disease for which safer drugs cannot be used or are ineffective.

SECOND Trimester

Class D - Adequate well-controlled or observational studies in pregnant women have demonstrated a risk to the fetus. However, the benefits of therapy may outweigh the potential risk. For example, the drug may be acceptable if needed in a life-threatening situation or serious disease for which safer drugs cannot be used or are ineffective.

THIRD Trimester

Class D - Adequate well-controlled or observational studies in pregnant women have demonstrated a risk to the fetus. However, the benefits of therapy may outweigh the potential risk. For example, the drug may be acceptable if needed in a life-threatening situation or serious disease for which safer drugs cannot be used or are ineffective.

Lactation

Avoid - This drug is known to cause harm to infants when taken by nursing mothers.


Learning More About
Visit the Drug Summary page where you can:
  • Get answers to Frequently Asked Questions (FAQs)
  • Find other class related drugs
  • Find additional patient usage statistics
Learn More
Patient Experiences with PERJETA

Be the first to share your experience!

We want to help our customers stay educated about the medications they are taking. Submit your own observations and experiences to benefit others.

Average Scores
Easy to Take 
0 / 5
0 / 5
Works as Intended 
0 / 5
0 / 5
Tolerable 
0 / 5
0 / 5